Direct-to-Consumer Advertising of Alzheimer’s Disease Drugs

DSpace/Manakin Repository

Direct-to-Consumer Advertising of Alzheimer’s Disease Drugs

Citable link to this page

 

 
Title: Direct-to-Consumer Advertising of Alzheimer’s Disease Drugs
Author: Arakawa, Chika
Citation: Chika Arakawa, Direct-to-Consumer Advertising of Alzheimer’s Disease Drugs (April 2, 20120.
Full Text & Related Files:
Abstract: Use of direct-to-consumer (DTC) advertising by pharmaceutical manufacturers has
skyrocketed in the past few decades as patients demand more information on drugs and
the FDA has gotten more relaxed in its regulation of such marketing. In particular,
television advertisements for prescription drugs for chronic conditions have dramatically
increased. This paper will analyze the use of DTC advertising for prescription drugs for
Alzheimer’s disease, a debilitating disease which can last for more than a decade before it
leads to death. The paper will start with a history of DTC advertising and the FDA’s
regulation of such advertisements. It will then proceed to analyze issues of DTC
advertising which are particularly pertinent for Alzheimer’s disease, with an in-depth
look at Aricept, one FDA-approved drug for Alzheimer’s. The paper will conclude with
suggestions for further studies in the area and a number of proposals for reform.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10985167
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters